Business Wire06.25.19
Repro Med Systems Inc. dba RMS Medical Products, has appointed R. John Fletcher as an independent member of the company's Board of Directors. With this appointment, RMS Medical’s Board of Directors fills the vacancy created by the passing of Arthur J. Radin.
Fletcher brings more than 35 years of healthcare and medical device experience to RMS Medical. He currently serves as CEO and managing director of Fletcher Spaght Inc., a strategy consulting and venture capital firm which he founded in 1983. Prior to founding Fletcher Spaght, he was senior manager at The Boston Consulting Group, advising a broad range of companies in healthcare and high technology industries.
Fletcher joined the Board of Directors of publicly-traded medical device company Spectranetics Corporation in 2002 and served as board chairman from 2010-2017. During his 15-year tenure as a member of the board, Spectranetics expanded its therapeutic platforms and generated significant commercial growth. In August 2017 Spectranetics was acquired by Royal Philips in a transaction valued at $2.2 billion. Fletcher was named 2018 Director of the Year by The National Association of Corporate Directors (NACD) for his work at Spectranetics.
“John’s vision and leadership in the medical device industry has helped improve the lives of patients around the world,” said Don Pettigrew, president and CEO of RMS Medical. “We believe he will be a significant asset as we continue to expand RMS Medical’s business and elevate our industry profile.”
Fletcher currently serves on the Board of Directors of Axcelis Corporation and MRI Interventions, and is chairman of Metabolon. He is Chairman Emeritus of the Corporate Collaboration Council at the Thayer School of Engineering/Tuck School of Business at Dartmouth College and serves on the Board of Advisors of Beth Israel Deaconess Medical Center and the Whitehead Institute at MIT.
“John is an industry veteran and brings to RMS Medical a proven record of building brands, teams and businesses, and advising growth-oriented public companies in the healthcare industry,” said Daniel S. Goldberger, executive chairman of RMS Medical. “I am thrilled and excited to welcome him to our board.”
Fletcher earned an MBA from Southern Illinois University and a BBA in marketing from George Washington University. He was an instructor for courses in international business and a Ph.D. candidate at the Wharton School of the University of Pennsylvania. Fletcher served as a captain and jet pilot in the United States Air Force.
“It’s an exciting time at RMS Medical and I am very pleased to join the Board of Directors,” said Fletcher. “The infusion therapy market is growing and I believe RMS Medical, with its portfolio of reliable, easy-to-use, and effective products, is well-positioned to participate in this anticipated industry growth.”
RMS Medical also announced that David W. Anderson has been appointed chairman of the Audit Committee. Anderson succeeds Arthur J. Radin. A member of the Board of Directors since 2016, Anderson is a seasoned healthcare executive with more than 23 years of experience in the medical device industry.
“David is a valued board member with a distinguished background in the healthcare industry, and we welcome him to his new position,” said Goldberger.
Fletcher will join the Audit Committee with Anderson and Robert Allen.
RMS Medical develops, manufactures and commercializes specialty infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System currently includes the FREEDOM60 and FreedomEdge Syringe Infusion Drivers, RMS Precision Flow Rate Tubing and RMS HIgH-Flo Subcutaneous Safety Needle Sets. These devices are used for infusions administered in the home and alternate care settings.
Fletcher brings more than 35 years of healthcare and medical device experience to RMS Medical. He currently serves as CEO and managing director of Fletcher Spaght Inc., a strategy consulting and venture capital firm which he founded in 1983. Prior to founding Fletcher Spaght, he was senior manager at The Boston Consulting Group, advising a broad range of companies in healthcare and high technology industries.
Fletcher joined the Board of Directors of publicly-traded medical device company Spectranetics Corporation in 2002 and served as board chairman from 2010-2017. During his 15-year tenure as a member of the board, Spectranetics expanded its therapeutic platforms and generated significant commercial growth. In August 2017 Spectranetics was acquired by Royal Philips in a transaction valued at $2.2 billion. Fletcher was named 2018 Director of the Year by The National Association of Corporate Directors (NACD) for his work at Spectranetics.
“John’s vision and leadership in the medical device industry has helped improve the lives of patients around the world,” said Don Pettigrew, president and CEO of RMS Medical. “We believe he will be a significant asset as we continue to expand RMS Medical’s business and elevate our industry profile.”
Fletcher currently serves on the Board of Directors of Axcelis Corporation and MRI Interventions, and is chairman of Metabolon. He is Chairman Emeritus of the Corporate Collaboration Council at the Thayer School of Engineering/Tuck School of Business at Dartmouth College and serves on the Board of Advisors of Beth Israel Deaconess Medical Center and the Whitehead Institute at MIT.
“John is an industry veteran and brings to RMS Medical a proven record of building brands, teams and businesses, and advising growth-oriented public companies in the healthcare industry,” said Daniel S. Goldberger, executive chairman of RMS Medical. “I am thrilled and excited to welcome him to our board.”
Fletcher earned an MBA from Southern Illinois University and a BBA in marketing from George Washington University. He was an instructor for courses in international business and a Ph.D. candidate at the Wharton School of the University of Pennsylvania. Fletcher served as a captain and jet pilot in the United States Air Force.
“It’s an exciting time at RMS Medical and I am very pleased to join the Board of Directors,” said Fletcher. “The infusion therapy market is growing and I believe RMS Medical, with its portfolio of reliable, easy-to-use, and effective products, is well-positioned to participate in this anticipated industry growth.”
RMS Medical also announced that David W. Anderson has been appointed chairman of the Audit Committee. Anderson succeeds Arthur J. Radin. A member of the Board of Directors since 2016, Anderson is a seasoned healthcare executive with more than 23 years of experience in the medical device industry.
“David is a valued board member with a distinguished background in the healthcare industry, and we welcome him to his new position,” said Goldberger.
Fletcher will join the Audit Committee with Anderson and Robert Allen.
RMS Medical develops, manufactures and commercializes specialty infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System currently includes the FREEDOM60 and FreedomEdge Syringe Infusion Drivers, RMS Precision Flow Rate Tubing and RMS HIgH-Flo Subcutaneous Safety Needle Sets. These devices are used for infusions administered in the home and alternate care settings.
